Therefore, we conducted this systematic review and meta-analysis to comprehensively assess the efficacy and safety of PI3K inhibitors combined with fulvestrant in advanced breast cancer, aiming to provide more reliable evidence-based recommendations for clinical practice. Here, PIK3CA is linked to breast cancer.